Geode Capital Management LLC bought a new position in shares of OnKure Therapeutics (NASDAQ:OKUR – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 76,599 shares of the company’s stock, valued at approximately $659,000. Geode Capital Management LLC owned 2.29% of OnKure Therapeutics at the end of the most recent reporting period.
Separately, Highbridge Capital Management LLC acquired a new stake in shares of OnKure Therapeutics during the fourth quarter worth about $3,438,000. Institutional investors own 90.98% of the company’s stock.
Wall Street Analyst Weigh In
A number of equities analysts have recently commented on the company. Oppenheimer lowered their price objective on OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating for the company in a research report on Tuesday, March 11th. Evercore ISI initiated coverage on shares of OnKure Therapeutics in a report on Wednesday. They issued an “outperform” rating on the stock. Finally, HC Wainwright lowered their price objective on shares of OnKure Therapeutics from $40.00 to $34.00 and set a “buy” rating on the stock in a research report on Tuesday, March 18th. Four equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $32.33.
OnKure Therapeutics Stock Performance
OKUR opened at $2.50 on Friday. OnKure Therapeutics has a one year low of $2.42 and a one year high of $20.00. The company has a market cap of $33.59 million, a price-to-earnings ratio of -0.20 and a beta of 0.35. The business’s fifty day moving average is $3.93 and its two-hundred day moving average is $8.62.
OnKure Therapeutics (NASDAQ:OKUR – Get Free Report) last posted its quarterly earnings data on Monday, March 10th. The company reported ($1.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.51). On average, analysts predict that OnKure Therapeutics will post -4.05 EPS for the current fiscal year.
About OnKure Therapeutics
OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.
Further Reading
- Five stocks we like better than OnKure Therapeutics
- What is the Shanghai Stock Exchange Composite Index?
- The Most Inspiring Small Businesses of 2025 [Survey]
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Microsoft Crushes Earnings, What’s Next for MSFT Stock?
- What is the S&P 500 and How It is Distinct from Other Indexes
- McDonald’s Insiders Sell Shares! Investors Should Do the Opposite
Want to see what other hedge funds are holding OKUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OnKure Therapeutics (NASDAQ:OKUR – Free Report).
Receive News & Ratings for OnKure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OnKure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
